Analytical chemistry · 2026
CHAI-sEV: A Programmable Hairpin-Driven Cas9 Platform with AI Integration for Dual-Protein Profiling and Intelligent Classification of Tumor-Derived Small Extracellular Vesicles.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Shen Haoyu, Pan Xinyu, Wu Yan, Chen Bing, Zhou Xiaolei, Qiao Linbo, Effah Clement Yaw, Zhou Jing, Yu Junying, Zhang Zhenzhong, Yang Xiaonan, Wu Yongjun, Ding Lihua
Аннотация
Multiplexed protein profiling of tumor-derived small extracellular vesicles (TsEVs) requires signal-conversion strategies that are sensitive, low-background, and orthogonal. Collateral-cleavage CRISPR assays based on Cas12a or Cas13a provide efficient amplification but can compromise single-pot multitarget detection, whereas the sequence-specific cleavage of Cas9 remains underexplored for converting vesicle-surface protein recognition into orthogonal amplified outputs. Here, we report CHAI-sEV, a programmable Cas9-mediated trigger-release strategy based on PAM-bearing hairpin-locking probes (PHLPs) for dual-protein profiling of TsEVs. Each PHLP integrates Cas9 recognition and signal conversion into a single molecular substrate, in which sgRNA-guided Cas9 cleavage unlocks a sequestered CHA activator to initiate orthogonal signal amplification. After EGFR- or PD-L1-binding aptamers label TsEVs, engineered aptamer tails recruit specific Cas9-sgRNA complexes to the vesicle surface, enabling protein-specific PHLP activation and amplified fluorescence readout. This Cas9-programmed trigger-release mechanism enables dual-channel TsEV protein detection without relying on nonspecific collateral cleavage. Under optimized conditions, CHAI-sEV achieved detection limits of 162 and 328 particles/μL for EGFR and PD-L1. In plasma samples, CHAI-sEV differentiated lung cancer patients from benign-lung-disease patients and healthy controls and showed decreased EGFR and PD-L1 signals in post-treatment samples. As proof-of-concept extensions, the CHAI-sEV was further coupled to an IGZO-FET electrical readout and an exploratory machine-learning analysis combining dual-protein signals with clinical features. Overall, PHLPs provide a substrate-design principle that converts Cas9 cleavage into amplification-compatible and orthogonally multiplexable biosensing outputs, enabling sensitive and multiplexed protein profiling of TsEVs and offering potential for extension to diverse molecular targets.